UNSPSC 51292501: Flibanserin

This classification denotes a serotonin antagonist with the molecular formula C20H21F3N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37JK4STR6Z, chemically known as 1,3-dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2h-benzimidazol-2-one but generally known as flibanserin, which bears US NIH Compound Identifier 127941. European Medicines Agency schedules Flibanserin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07644MIG.

UNSPSC 51292501 Flibanserin, a Commodity code, nominally designates a single pharmaceutical product, yet recent state and local procurement under this code shows little activity aligned with flibanserin specifically. Instead, the opportunities posted reflect broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products. State and local governments procuring under pharmaceutical commodity codes are chiefly county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the kinds of issuing bodies active in this space. The scope of work spans tactical public-health purchases (naloxone kits for harm reduction), exploratory state-level procurement strategy (direct-to-manufacturer relationships), and high-volume generic drug supply agreements serving health systems and government employee benefit plans across state lines.

Recent opportunities span Florida, Texas, and Minnesota, with multistate cooperative purchasing extending the geographic reach to include participating states such as Oregon. Seminole County posted IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023 (note: the due date appears inconsistent with the post date). The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs, a market-intelligence phase preceding formal competitive solicitation. The Minnesota Department of Administration's MMCAP posted RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with contracts effective July 1, 2026, and vendor pricing weighted at 75 percent of the evaluation. Bidders must comply with cGMP, Drug Supply Chain Security Act certification, E-Verify, drug-free workplace requirements, and specified insurance minimums; contracts typically run two years with renewal options.